Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 23, 2020, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2020.

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results

Pasadena. CA | Posted on November 3rd, 2020

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 8492751.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 8492751.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Phytoplankton disturbed by nanoparticles: Due to its antibacterial properties, nanosilver is used in a wide range of products from textiles to cosmetics; but nanosilver if present at high concentrations also disrupts the metabolism of algae that are essential for the aquatic food November 27th, 2020

Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research November 27th, 2020

One-way street for electrons: Scientists observe directed energy transport between neighbouring molecules in a nanomaterial November 27th, 2020

New insights into memristive devices by combining incipient ferroelectrics and graphene November 27th, 2020

Possible Futures

Russian scientists improve 3D printing technology for aerospace composites using oil waste November 27th, 2020

Phytoplankton disturbed by nanoparticles: Due to its antibacterial properties, nanosilver is used in a wide range of products from textiles to cosmetics; but nanosilver if present at high concentrations also disrupts the metabolism of algae that are essential for the aquatic food November 27th, 2020

Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research November 27th, 2020

One-way street for electrons: Scientists observe directed energy transport between neighbouring molecules in a nanomaterial November 27th, 2020

Investments/IPO's/Splits

180 Degree Capital Corp. Reports +7.4% Growth and $2.90 Per Share NAV as of September 30, 2020, and Developments From Q4 2020 November 19th, 2020

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 29th, 2020

180 Degree Capital Corp. Invests Additional Capital in TheMaven, Inc. and Provides QTD Public Portfolio Update (+22.1% / +$0.32 Per Share) September 10th, 2020

Nanogate: Meeting of creditors on November 4, 2020 September 4th, 2020

Nanomedicine

An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target November 27th, 2020

Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research November 27th, 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results November 23rd, 2020

Announcements

Phytoplankton disturbed by nanoparticles: Due to its antibacterial properties, nanosilver is used in a wide range of products from textiles to cosmetics; but nanosilver if present at high concentrations also disrupts the metabolism of algae that are essential for the aquatic food November 27th, 2020

Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research November 27th, 2020

One-way street for electrons: Scientists observe directed energy transport between neighbouring molecules in a nanomaterial November 27th, 2020

New insights into memristive devices by combining incipient ferroelectrics and graphene November 27th, 2020

Financial Reports

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results November 23rd, 2020

180 Degree Capital Corp. Reports +7.4% Growth and $2.90 Per Share NAV as of September 30, 2020, and Developments From Q4 2020 November 19th, 2020

180 Degree Capital Corp. to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 and to Host a Conference Call on Tuesday, August 11, 2020 August 7th, 2020

180 Degree Capital Corp. Reports Q1 2020 Results and Developments From Q2 2020 May 6th, 2020

Events/Classes

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results November 23rd, 2020

Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020 November 13th, 2020

CEA-Leti to Present Latest Results & Insights on 3D Technologies, Power Electronics & Quantum Computing: Institute’s Experts to Host Online Tutorial on Qubit Figures of Merit And Short Course on 3D Sequential Integration November 9th, 2020

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 November 6th, 2020

Nanobiotechnology

An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target November 27th, 2020

Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research November 27th, 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results November 23rd, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project